Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes.
about
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Abiraterone acetate and predni ...... r impact on clinical outcomes.
@en
Abiraterone acetate and predni ...... r impact on clinical outcomes.
@nl
type
label
Abiraterone acetate and predni ...... r impact on clinical outcomes.
@en
Abiraterone acetate and predni ...... r impact on clinical outcomes.
@nl
prefLabel
Abiraterone acetate and predni ...... r impact on clinical outcomes.
@en
Abiraterone acetate and predni ...... r impact on clinical outcomes.
@nl
P2093
P2860
P50
P356
P1476
Abiraterone acetate and predni ...... r impact on clinical outcomes.
@en
P2093
Alessandra Rubagotti
Antonio Di Meglio
Carlo Messina
Chiara Fabbroni
Eleonora Arboscello
Elisa Zanardi
Francesco Boccardo
Linda Zinoli
Paolo Spallarossa
P2860
P304
1758834017745819
P356
10.1177/1758834017745819
P577
2018-01-09T00:00:00Z